Pharmaceutical Sector Update: The pharmaceutical industry is experiencing significant activity due to the recent passage of a new law in the United States known as the Biosecure Act. This pivotal legislation, approved by the US House of Representatives on September 9, aims to reduce American pharmaceutical companies’ reliance on China and restrict the transfer of critical technology. As the Biosecure Act moves to the US Senate for final approval, experts anticipate a notable impact on Indian pharma stocks, potentially leading to substantial gains.
The Biosecure Act specifically targets five major Chinese companies – WuXi Apptec, Wuxi Biologics, BGI, MGI, and Complete Genomics. Should American companies continue partnerships with these firms, they risk losing access to essential grants, loans, or contracts from the US government. This legislative change could prompt investigations into roughly 120 American biopharmaceutical products, further underscoring the act’s significance.
Who Stands to Gain?
The primary beneficiaries of the Biosecure Act are Indian pharmaceutical companies, particularly those specializing in the Contract Development and Manufacturing (CDMO) sector. CDMO companies manufacture drugs for other firms under contractual agreements, positioning them as ideal alternatives to Chinese manufacturers as the US seeks to diversify its pharmaceutical supply chains.
Key Players in the Indian Pharma CDMO Market
Several prominent Indian pharmaceutical companies excel in the CDMO space, including:
- Divi’s Laboratories
- Laurus Labs
- Neuland Laboratories
- Syngene International
- Suven Pharmaceuticals
- Piramal Pharma
These companies are poised to capitalize on the growing demand for contract manufacturing solutions as American firms reevaluate their supply chains in light of the Biosecure Act.
Market Growth and Future Outlook
According to Increase Equities, the CDMO market is set for rapid growth, driven by biopharmaceutical companies’ lack of capital for establishing manufacturing facilities. This trend encourages these companies to seek contract manufacturing options in countries like India, presenting a lucrative opportunity for Indian firms.
Evidence of this shift is already emerging. Noteworthy US pharmaceutical companies, including Beigene and Eli Lilly, are actively searching for CDMO partners outside of China. Following the announcement of the Biosecure Act, Indian CDMO firms have reported an influx of inquiries for new orders, reflected in an immediate 3-4 percent rise in the stock prices of these companies.
Current Activities and Competition
While Laurus Labs and Piramal Pharma are initiating smaller projects, Neuland Labs is engaging in increased discussions with US firms. However, large-scale orders have yet to materialize. Meanwhile, Syngene boasts a competitive advantage with long-term contracts already established. The company reported a 50 percent increase in requests for proposals (RFPs) in the first quarter of this year, marking its best performance over the last four years.
Projected Growth in the CDMO Sector
The CDMO industry in India is on an upward trajectory, with InCred Equities projecting its market size to expand from $19.63 billion in 2023 to $44.69 billion by 2029, reflecting an annual growth rate of approximately 15 percent. This growth is further bolstered by supportive government initiatives such as the Production-Linked Incentive (PLI) scheme, foreign direct investment (FDI), and increased capital expenditures.
Disclaimer: The views and investment advice provided by experts or brokerage firms are their own and do not reflect the views of the website or its management. It is advised to consult certified experts before making any investment decisions.
